Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Low Grade Neuroendocrine Tumors
NCT00027638Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2001
- Primary completion
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in Neuroendocrine Neoplasm (NEN), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00027638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027638.